AstraZeneca to cut 2,300 more jobs, mostly in Europe

AstraZeneca offices in England. The firm, which also has facilitiesin Delaware, announced more job cuts.
AstraZeneca offices in England. The firm, which also has facilitiesin Delaware, announced more job cuts.
Posted: March 23, 2013

The drugmaker AstraZeneca, which announced big job cuts Monday in research and development, said Thursday morning that it was would lay off 2,300 more people from sales and administrative departments over the next three years throughout its worldwide operation.

AstraZeneca has facilities in Wilmington and Newark, Del. A company spokesman declined to specify the immediate local impact.

The spokesman said that the majority of the 2,300 workers had been notified or soon would be, and that those people were largely in sales in Europe. The rest of the cuts will be determined over the next three years. The company had not decided which people, departments, or locations would be affected, he said.

On Monday, the British-based company said its reorganization plans for research and development involve moving or cutting about 1,200 jobs from the facility in Wilmington. About 650 positions will be eliminated, with about 300 others moving to Gaithersburg, Md., and about 170 more moving elsewhere in the global system. The company also said it would move its headquarters from London to near Cambridge, England, and make other changes to its roster of facilities.

The company has been cutting jobs in phases. The latest, or fourth, phase involves eliminating 5,050 positions from 2013 through 2016.

Meanwhile, AstraZeneca announced that it struck a $420 million deal with Moderna Therapeutics, a relatively new biotech company in Cambridge, Mass. The deal is an attempt to improve the pipeline of new medicine and revenue. There will be $240 million paid up front and $180 million in milestone payments as drugs are developed.

The reorganization, which included Pascal Soriot's joining the company as chief executive officer in October, is meant to reverse the revenue declines prompted by highly profitable medicines losing patent protection and, thus, market exclusivity. Several other products will lose that protection in the next few years.


Contact David Sell

at dsell@ phillynews.com

or 215-854-4506. Read his blog at www.philly.com/ phillypharma and on Twitter @phillypharma.

comments powered by Disqus
|
|
|
|
|